Related Experiment Videos
Carbamazepine-induced leukocytosis
American Journal of Hospital Pharmacy
|April 1, 1980
Summary
Carbamazepine, an epilepsy medication, was linked to a significant increase in white blood cell (WBC) count, a condition known as leukocytosis. Discontinuation and reintroduction of the drug confirmed its role in causing this adverse effect.
Area of Science:
- Neurology
- Hematology
- Clinical Pharmacology
Background:
- Carbamazepine is a widely prescribed anticonvulsant medication used for epilepsy and other neurological conditions.
- Leukocytosis, an elevated white blood cell count, can be a sign of infection, inflammation, or other underlying medical issues.
Observation:
- A 26-year-old woman presented with a significantly elevated white blood cell (WBC) count of 21.2 x 10(3)/cu mm while on carbamazepine therapy.
- Her WBC count normalized after switching to phenytoin and phenobarbital.
- Upon reintroduction of carbamazepine, her WBC count again became significantly elevated, suggesting a causal link.
Findings:
- The case presents a strong correlation between carbamazepine administration and the development of leukocytosis.
- Rechallenge with carbamazepine confirmed its probable role in inducing the elevated WBC count.
- Other co-administered medications did not appear to be the primary cause of the observed leukocytosis.
Implications:
- This case highlights the importance of considering drug-induced leukocytosis, specifically from carbamazepine, in patients presenting with elevated WBC counts.
- Physicians should be vigilant for this potential adverse effect and consider medication review and adjustment.
- Further investigation into the mechanisms of carbamazepine-induced leukocytosis may be warranted.